JupiteX Get the app
Health & Medicine18 Nov 2026 · about 7 min

Can South Africa Tackle HIV Without the U.S.?

The brief

South Africa already funds most of its HIV response, but PEPFAR’s withdrawal removes a major source of support just as the country rolls out a promising prevention drug. That makes lenacapavir a practical test of whether existing systems can deliver new protection amid reduced U.S. aid. Lenacapavir is pre-exposure prophylaxis, or PrEP, for people who are HIV-negative. Its twice-yearly injection can replace daily pills, offering longer-lasting protection. The trial led by Linda-Gail Bekker drew a standing ovation in July 2024, but the rollout began after U.S. policy shifted and relations between the governments worsened. South Africa has around 8 million people living with HIV and still records about 170,000 new infections each year. It pays for most HIV programs and 90 percent of its antiretroviral drugs, yet PEPFAR supported services and workers. Officials cite self-reliance measures but have not released a formal plan. The rollout will show how well the transition works.

01

Why is South Africa’s rollout of lenacapavir an early test of its ability to manage HIV without PEPFAR?

South Africa already funds most of its HIV response, but PEPFAR’s withdrawal removes a major source of support just as the country rolls out a promising prevention drug. That makes lenacapavir a practical test of whether existing systems can deliver new protection amid reduced U.S. aid.

Lenacapavir is pre-exposure prophylaxis, or PrEP, for people who are HIV-negative. Its twice-yearly injection can replace daily pills, offering longer-lasting protection. The trial led by Linda-Gail Bekker drew a standing ovation in July 2024, but the rollout began after U.S. policy shifted and relations between the governments worsened.

South Africa has around 8 million people living with HIV and still records about 170,000 new infections each year. It pays for most HIV programs and 90 percent of its antiretroviral drugs, yet PEPFAR supported services and workers. Officials cite self-reliance measures but have not released a formal plan. The rollout will show how well the transition works.

02

What is lenacapavir, and how can a twice-yearly PrEP injection help prevent HIV?

Lenacapavir is a form of pre-exposure prophylaxis, or PrEP. PrEP is used by people who are HIV-negative to help prevent HIV infection. The article describes lenacapavir as a groundbreaking drug tested in South Africa, where HIV remains widespread.

The practical difference is how often it is taken. Lenacapavir is given as an injection twice a year, rather than requiring daily pills. That longer-lasting protection could make prevention easier to maintain and help slow the virus’s spread. In a major South African clinical trial led by Linda-Gail Bekker, the results prompted a standing ovation at an international AIDS conference in July 2024.

South Africa began rolling out the drug as PEPFAR funding was being phased out. The launch therefore tests not only a new prevention option but also the country’s ability to deliver it amid financial and political uncertainty. The article does not provide rollout numbers or detail who will receive the first injections, so the reach of the program remains unclear.

03

How large is South Africa’s HIV epidemic, and how many new infections does it record each year?

South Africa is home to around 8 million people living with HIV, making it the country at the center of the global epidemic described in the article. Those 8 million people account for around 20 percent of the world’s HIV population. The scale matters because prevention and treatment must reach millions of people.

Approximately 6 million people in South Africa are on treatment. Even so, the country records around 170,000 new HIV infections each year. The figures show two parts of the challenge: supporting people already living with HIV while also preventing new infections. Lenacapavir is one new prevention option being introduced.

The article describes this rollout as an early test of South Africa’s ability to manage its HIV response after PEPFAR funding ends. The country already pays for most of its HIV programs and 90 percent of its antiretroviral drugs, but the loss of U.S. support has disrupted services. The continuing number of new infections makes sustained prevention especially important.

04

What could happen to clinics, health workers, and HIV services as PEPFAR funding ends?

PEPFAR has supported South Africa’s HIV response for years, providing around $8 billion since 2003. Although South Africa pays for most of its own HIV programs, the loss of U.S. support has had immediate effects. The article reports that clinics serving high-risk groups have closed and thousands of health workers have lost their jobs.

The funding picture has worsened quickly. The United States provided South Africa with $115 million last year to keep core HIV services running. In June, the Trump administration said it would end all PEPFAR funding for the country in the coming months. The administration also excluded South Africa from health financing deals made with other African countries.

As funding ends, clinics and services that rely on that support could face more disruption, while staff losses may make care harder to deliver. The article does not quantify what further closures or service gaps will occur. South African officials say they have been working toward self-reliance, but have not released a formal plan. Local manufacturing, stronger public systems, and regional cooperation are among the approaches they cite.

05

How dependent was South Africa on PEPFAR compared with neighboring countries, and what HIV care does it already pay for itself?

South Africa entered the funding transition less dependent on PEPFAR than some nearby countries. PEPFAR provided less than 25 percent of South Africa’s HIV prevention funding, while the share was around 80 percent in neighboring Mozambique and Zimbabwe. That head start may help, but it does not mean the loss of U.S. support has no consequences.

The country already pays for most of its own HIV programs, including 90 percent of its antiretroviral drugs. It has around 8 million people living with HIV, and approximately 6 million are on treatment. Yet the withdrawal has already shuttered clinics serving high-risk groups and left thousands of health workers without jobs.

The U.S. State Department says South Africa can support its own health programs as a middle-income country. South African officials point to self-reliance, local drug manufacturing, stronger public health systems, and regional collaboration. They have not released a formal plan, so the details of how these approaches will replace lost support remain uncertain.

06

What approaches could help South Africa sustain its HIV response without U.S. funding?

South Africa’s response to the loss of PEPFAR support depends on whether it can sustain HIV services with less U.S. funding. Officials say the government has long been working on a self-reliance plan. The need is pressing: PEPFAR’s collapse has shuttered clinics for high-risk groups and left thousands of health workers without jobs.

Officials identify three approaches: local drug manufacturing, stronger public health systems, and regional collaboration on HIV. These are intended to help the country maintain services and rely less on outside support. South Africa already pays for most of its HIV programs, including 90 percent of its antiretroviral drugs, and PEPFAR made up less than 25 percent of its HIV prevention funding.

However, officials have not released a formal plan explaining how the approaches will be carried out. The United States said it would end all PEPFAR funding for South Africa in the coming months and excluded it from some financing deals with other African countries. The lenacapavir rollout is an early test of this transition, but the article does not establish whether these measures will fill the funding gap.

07

How do PrEP, which helps prevent HIV, and antiretroviral treatment, which helps people living with HIV, play different roles in controlling an epidemic?

PrEP and antiretroviral treatment play different roles in an HIV epidemic. PrEP is prevention for people who are HIV-negative: the article says it blocks the virus from spreading in them. Antiretroviral treatment, by contrast, is care for people already living with HIV. Both matter because a response must address new infections and support people who have HIV.

Lenacapavir is the article’s example of PrEP. It is given as an injection twice a year and could replace daily prevention pills, offering longer-lasting protection. For treatment, the article reports that approximately 6 million of South Africa’s around 8 million people living with HIV are on treatment. South Africa pays for 90 percent of its antiretroviral drugs.

The article does not explain the treatment mechanism; in general, antiretroviral treatment uses medicines to control HIV in people who have it. PrEP does not treat HIV, and treatment is not the same as taking PrEP to prevent infection. South Africa needs both roles in its response, especially as it records around 170,000 new infections each year and faces the loss of PEPFAR funding.

This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.

Read more in the JupiteX app

Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.

Or read more news on the web